Tumoral vascularity as a prognostic factor in cancer.
Weidner
N
N
University of California, San Francisco, USA.
Folkman
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D016228:Endothelial Growth Factors / Q000502:physiology; D004730:Endothelium, Vascular / Q000737:chemistry; D006801:Humans; D015993:Life Tables; D008222:Lymphokines / Q000502:physiology; D008833:Microcirculation; D009361:Neoplasm Invasiveness / Q000503:physiopathology; D009362:Neoplasm Metastasis / Q000503:physiopathology; D009363:Neoplasm Proteins / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000401:mortality; D009360:Neoplastic Cells, Circulating; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis; D017978:Receptors, Growth Factor / Q000502:physiology; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D015415:Biomarkers; D016228:Endothelial Growth Factors; D008222:Lymphokines; D009363:Neoplasm Proteins; D017978:Receptors, Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors